7 Results for "

APP mRNA

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "APP mRNA" in MCE Product Catalog:

  • Targets Recommended:
1
1 Cited Publications
Cat. No.: HY-16009
CAS No.: 116839-68-0
Synonyms: (+)-Phenserine; ANVS401
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16009B
CAS No.: 865795-23-9
Synonyms: (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-401209
CAS No.: 613226-91-8
Research Areas:  

Neurological Disease

Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC50 of 2.9 µM and a Kd value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease .
loading...
    loading...
Cat. No.: HY-177646
CAS No.: 2572991-83-2
Synonyms: ALN-APP
Mivelsiran (ALN-APP) is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran can be used for research on early-onset Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177646A
Synonyms: ALN-APP sodium
Mivelsiran (ALN-APP) sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177646C
Research Areas:  

Neurological Disease

FAM labled Mivelsiran (ALN-APP) sodiumis a FAM labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177646D
Research Areas:  

Neurological Disease

Cy3 labled Mivelsiran (ALN-APP) sodium is a Cy3 labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
loading...
    loading...